Two-way Pharmacodynamic Modeling of Drug Combinations and Its Application to Pairs of Repurposed Ebola and SARS-CoV-2 Agents
Overview
Authors
Affiliations
Existing pharmacodynamic (PD) mathematical models for drug combinations discriminate antagonistic, additive, multiplicative, and synergistic effects, but fail to consider how concentration-dependent drug interaction effects may vary across an entire dose-response matrix. We developed a two-way pharmacodynamic (TWPD) model to capture the PD of two-drug combinations. TWPD captures interactions between upstream and downstream drugs that act on different stages of viral replication, by quantifying upstream drug efficacy and concentration-dependent effects on downstream drug pharmacodynamic parameters. We applied TWPD to previously published drug matrixes for repurposed potential anti-Ebola and anti-SARS-CoV-2 drug pairs. Depending on the drug pairing, the model recapitulated combined efficacies as or more accurately than existing models and can be used to infer efficacy at untested drug concentrations. TWPD fits the data slightly better in one direction for all drug pairs, meaning that we can tentatively infer the upstream drug. Based on its high accuracy, TWPD could be used in concert with PK models to estimate the therapeutic effects of drug pairs .
Efficient assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains.
Woodall M, Ellis S, Zhang S, Kembou-Ringert J, Kite K, Buggiotti L Antimicrob Agents Chemother. 2024; 69(2):e0123324.
PMID: 39688407 PMC: 11823597. DOI: 10.1128/aac.01233-24.
Esmaeili S, Owens K, Wagoner J, Polyak S, White J, Schiffer J Nat Commun. 2024; 15(1):5478.
PMID: 38942778 PMC: 11213957. DOI: 10.1038/s41467-024-49458-9.
Esmaeili S, Owens K, Wagoner J, Polyak S, White J, Schiffer J medRxiv. 2024; .
PMID: 38352583 PMC: 10862980. DOI: 10.1101/2023.08.23.23294505.